middle.news

How Is Syntara’s Amsulostat Shaping the Future of Blood Cancer Treatment?

2:24pm on Wednesday 30th of July, 2025 AEST Healthcare
Read Story

How Is Syntara’s Amsulostat Shaping the Future of Blood Cancer Treatment?

2:24pm on Wednesday 30th of July, 2025 AEST
Key Points
  • Positive interim Phase 2 data for amsulostat in myelofibrosis
  • FDA grants Fast Track designation for amsulostat
  • Phase 1b/2 trial initiated for amsulostat in myelodysplastic syndrome
  • First patient dosed in Phase 1c trial for keloid scars
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Syntara (ASX:SNT)
OPEN ARTICLE